Merus N.V.
merus.nlNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Oct 31, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Feb 17, 2026.
10-Q for Q3 FY2025, filed Oct 31, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops multispecific antibody medicines for cancer and licenses antibody candidates and antibody platforms to pharmaceutical partners.
10-K for FY2024, filed Feb 27, 2025We are an oncology company developing innovative antibody therapeutics. Our pipeline of full-length, human, multispecific antibody…View ↗
Using our Biclonics® platform we have produced, and are currently developing, the following candidates: Petosemtamab (MCLA-158) for the…View ↗
Successfully commercialize our most advanced bispecific antibody candidate, zenocutuzumab (Zeno), through our collaboration with Partner…View ↗
Accelerate the discovery and development of additional internal and collaboration-related Multiclonics®, bispecific antibody candidates and…View ↗
Seek strategic collaborations. We intend to seek strategic collaborations to facilitate the capital-efficient development of our pipeline…View ↗
How Did They Make Money?
Merus receives collaboration income from pharmaceutical partners for licenses to antibody candidates and research and development services. License fees may be due upfront or when a partner exercises an option or extends a selection period; agreements may also provide milestones and royalties tied to product sales.
10-K for FY2024, filed Feb 27, 2025The Company has entered into collaboration and license agreements, which are within the scope of ASC 606, Revenue from Contracts with…View ↗
If the license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations…View ↗
The Company’s arrangements may provide the collaboration partner with the right to select a target for licensing either at the inception of…View ↗
For arrangements that include sales-based milestones and royalties, and the license is deemed to be the predominant item to which the…View ↗
Research and Development ServicesView ↗
$36.1M
-
10-K for FY2024, filed Feb 27, 2025
$36.1M ↗
Who Were Their Customers?
Pharmaceutical companies collaborate directly with Merus to research, develop and license antibody candidates; Partner Therapeutics holds U.S. commercialization rights to zenocutuzumab, and Betta holds China rights to MCLA-129.
10-K for FY2024, filed Feb 27, 2025Successfully commercialize our most advanced bispecific antibody candidate, zenocutuzumab (Zeno), through our collaboration with Partner…View ↗
Successfully develop our bispecific antibody candidate MCLA-129. We are developing MCLA-129 as a potential treatment for solid tumors…View ↗
Accelerate the discovery and development of additional internal and collaboration-related Multiclonics®, bispecific antibody candidates and…View ↗
Seek strategic collaborations. We intend to seek strategic collaborations to facilitate the capital-efficient development of our pipeline…View ↗
Sales and MarketingView ↗
Did Revenues Turn Into Profits?
No. It lost $215.3M in FY2024.
10-K for FY2024, filed Feb 27, 2025
−$272.1MView ↗
10-K for FY2024, filed Feb 27, 2025
−$215.3MView ↗
10-K for FY2024, filed Feb 27, 2025
−$187.5MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Oct 31, 2025
−$95.5MView ↗
- ▼ −4% (Loss)
- vs −$99.9M in Q3 FY2024
-
Dec 30, 2025
Genmab completed its acquisition of Merus
The back-end merger and cancellation converted remaining shares into a right to receive cash.
Sources
8-K, filed Dec 30, 2025
As previously disclosed by Merus N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The…View ↗
-
Dec 12, 2025
Genmab took control and Merus's CEO departed
At closing, Purchaser owned 94.2% of shares; Sven (Bill) Ante Lundberg ceased to be an executive officer.
Sources
8-K, filed Dec 12, 2025
On December 12, 2025, as of the Closing, Purchaser owned a total of 71,463,077 Common Shares, collectively representing approximately 94.2%…View ↗
Grew. Revenue grew 21% in 4 years, from $29.9M in FY2020 to $36.1M in FY2024, about 5% a year.
Zenocutuzumab reaches the market
Earlier, Merus described zenocutuzumab as a development candidate; the latest report says it has FDA approval for specified cancers and licenses its commercialization in the United States to Partner Therapeutics.
10-K for FY2021, filed Feb 28, 2022 10-K for FY2024, filed Feb 27, 2025
Pipeline emphasis
Earlier, Merus framed zenocutuzumab as its most advanced program; the latest report identifies petosemtamab as its lead candidate and describes registrational trials for it.
10-K for FY2021, filed Feb 28, 2022 10-K for FY2024, filed Feb 27, 2025Successfully develop our most advanced bispecific antibody candidate, zenocutuzumab, for the treatment of NRG1 fusion solid tumors. We are…View ↗
Successfully develop our lead bispecific antibody candidate petosemtamab, MCLA-158. We are developing petosemtamab for a potential dual…View ↗
Adds drug-linked antibodies
The latest report adds antibodies linked to cancer-killing drugs to the platform and describes a Biohaven collaboration to develop them; the earlier report focused on bispecific and trispecific antibodies.
10-K for FY2021, filed Feb 28, 2022 10-K for FY2024, filed Feb 27, 2025We are an oncology company developing innovative antibody therapeutics. Our pipeline of full-length, human, multispecific antibody…View ↗
Accelerate the discovery and development of additional internal and collaboration-related Multiclonics®, bispecific antibody candidates and…View ↗
Seek strategic collaborations. We intend to seek strategic collaborations to facilitate the capital-efficient development of our pipeline…View ↗
Who Did They Compete With?
Competes with Genmab, Regeneron Pharmaceuticals, Bicara Therapeutics, Exelixis, Pfizer, and Xencor
10-K for FY2024, filed Feb 27, 2025In addition to currently marketed therapies, there are also a number of products in late-stage clinical development to treat cancer…View ↗
Loading...
